Join us for AMCP Nexus 2025 in National Harbor from October 27-30, 2025. Watch video sizzle reel!
Best Practice Handout – Health Plan Best Practice – Biomarker Testing in Non-Small Cell Lung Cancer (NSCLC)
Summary Framework for Improving Precision Oncology in NSCLC Findings From The AMCP Market Insights Program
The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.
For more disease state research, view the Market Insights Program.
Related
AMCP strongly supports the passage of the MVP Act. Medicaid beneficiaries are among America's most vulnerable patients. Value-based payment arrangements are a critical tool for promoting patient access to high-quality, affordable care.
AMCP supports the Ensuring Community Access to Pharmacist Services Act. This bill will help ensure that Americans can continue to rely on pharmacists as essential partners in pandemic preparedness and response. The ECAPS Act will also improve patient access to tests and treatments by authorizing pharmacists to provide these services and receive reimbursement under Medicare Part B. The ECAPS Act addresses disparities in public health preparedness in medically underserved communities like rural areas by allowing these patients to seek care from their most accessible provider.
Featured News & Resources
See Full Calendar
Other Events
2026 Call for AMCP Board Applications
National Meetings
Midwest AMCP Chicago Day of Education
Upcoming Events
AMCP offers a wide variety of educational opportunities, from events and webinars to online training.
